← All Topics / ade

FDA ADE reports for Polysulfated Glycosaminoglycan (PSGAG disease-modifying osteoarthritis agent (intra-articular, dogs)) — total reports, species & reaction breakdown

ade_polysulfated_glycosaminoglycan_adverse_events

ade en 2026-07-22

Polysulfated Glycosaminoglycan — FDA Animal & Veterinary Adverse Event (ADE) Reports

Source: openFDA animalandveterinary/event.json, the FDA Center for Veterinary Medicine (CVM) adverse event report database. Data pulled 2026-07-22. Counts are report-level: one report may list multiple reactions and multiple animals, so figures are not additive and do not imply causation. Polysulfated Glycosaminoglycan is a PSGAG disease-modifying osteoarthritis agent (intra-articular, dogs).

Total reports

Polysulfated Glycosaminoglycan: 5761

Reports by species (top entries)

  • Dog 3955
  • Horse 415
  • Cat 312
  • Human 27
  • Other Birds 7
  • Other 6

Top reported reactions (VEDDRA terms, top entries)

  • Vomiting 1065
  • Diarrhoea 763
  • Product Defect, General 595
  • Lack of efficacy - NOS 572
  • Lethargy (see also Central nervous system depression in 'Neurological') 526
  • Not eating 380
  • Death by euthanasia 296
  • Color, Abnormal 267
  • Lethargy (see also Central nervous system depression in Neurological) 245
  • Elevated alanine aminotransferase (ALT) 238

"Lack of efficacy" terms denote product-performance reports, not adverse reactions.

Source JSON: pdf-raw/ade/ade_active_ingredients_2026-07-22_b8.json (openFDA animalandveterinary/event.json, pulled 2026-07-22).

Sources

  • openFDA animalandveterinary/event.json (FDA CVM ADE), pulled 2026-07-22